In a nutshell This study aimed to investigate if using both an angiotensin converting enzyme (ACE) inhibitor and a dipeptidyl peptidase 4 inhibitor, alogliptin (Nesina) in type 2 diabetes mellitus patients with recent acute coronary syndrome led to increased risk of cardiovascular events. This study concluded there was no increased risk of...
Read MoreCan using two inhibitors increase the risk of heart related events in diabetes patients?
